Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

21.56
-0.1600-0.74%
Post-market: 21.13-0.4300-1.99%17:14 EDT
Volume:807.26K
Turnover:17.44M
Market Cap:3.68B
PE:9.82
High:21.96
Open:21.71
Low:21.45
Close:21.72
52wk High:28.35
52wk Low:19.69
Shares:170.49M
Float Shares:115.85M
Volume Ratio:0.62
T/O Rate:0.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:37.32%
ROA:3.69%
PB:2.95
PE(LYR):9.37

Loading ...

Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 28

Acadia presents Phase 4 LOTUS real-world DAYBUE data in Rett syndrome at AAN 2026

Reuters
·
Apr 17

Bank of America Securities Remains a Buy on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 16

Acadia Pharmaceuticals to report first-quarter results after US market close

Reuters
·
Apr 16

Did DAYBUE STIX’s Flexible Rett Formulation Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative?

Simply Wall St.
·
Apr 16

A Look At Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX US Launch

Simply Wall St.
·
Apr 11

RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 09

Acadia Pharmaceuticals announces Daybue Stix available in U.S.

TIPRANKS
·
Apr 07

ACADIA Pharmaceuticals Announces Daybue® Stix (Trofinetide) Is NOW Broadly Available in the United States for the Treatment of Rett Syndrome

THOMSON REUTERS
·
Apr 07

RBC Capital Adjusts ACADIA Pharmaceuticals PT to $29 From $30, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

ACADIA Pharmaceuticals Shares Rise After BofA Upgrade

MT Newswires Live
·
Mar 26

BofA Securities Upgrades ACADIA Pharmaceuticals to Buy From Neutral, Price Target is $29

MT Newswires Live
·
Mar 25

ACADIA Pharmaceuticals Raised to Buy From Neutral by B of A Securities

Dow Jones
·
Mar 25

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Reuters
·
Mar 25

Acadia Pharmaceuticals' Remlifanserin Shows Favorable Setup Ahead of Phase 2 Data, RBC Says

MT Newswires Live
·
Mar 24

RBC Capital Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Mar 24

ACADIA Pharmaceuticals director Jonathan Poole files initial beneficial ownership statement

Reuters
·
Mar 21

ACADIA Pharmaceuticals appoints Jonathan M. Poole to board and audit committee

Reuters
·
Mar 05

ACADIA Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Mar 05

U.S. RESEARCH ROUNDUP-CrowdStrike, Oracle, Vulcan Materials

Reuters
·
Mar 04